{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:53:25Z","timestamp":1761058405146},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1016\/j.diagmicrobio.2005.09.004","type":"journal-article","created":{"date-parts":[[2006,2,4]],"date-time":"2006-02-04T15:29:32Z","timestamp":1139066972000},"page":"83-87","source":"Crossref","is-referenced-by-count":12,"title":["Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections"],"prefix":"10.1016","volume":"54","author":[{"given":"Beth P.","family":"Goldstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Fritsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas J.","family":"Biedenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/0091270005280378","article-title":"Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide","author":"Buckwalter","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jac\/44.2.179","article-title":"In vitro and in vivo antibacterial activity of BI397, a new semi-synthetic glycopeptide antibiotic","volume":"44","author":"Candiani","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0196-6553(99)70031-3","article-title":"National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990\u2013May 1999","volume":"27","author":"Centers for Disease Control and Prevention","year":"1999","journal-title":"Am. J. Infect. Control"},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib4","series-title":"Performance standards for antimicrobial susceptibility testing. Document M100-S15","author":"Clinical and Laboratory Standards Institute","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.diagmicrobio.2004.03.014","article-title":"Molecular epidemiology of selected multidrug-resistant bacteria: A global report from the SENTRY Antimicrobial Surveillance Program","volume":"49","author":"Deshpande","year":"2004","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1086\/520192","article-title":"Nosocomial bloodstream infections in United States hospitals: A three-year analysis","volume":"29","author":"Edmond","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib7","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jama.269.5.598","article-title":"The epidemiology of intravenous vancomycin usage in a university hospital: A 10-year study","volume":"269","author":"Ena","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib8","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1128\/AAC.48.4.1118-1123.2004","article-title":"Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model","volume":"48","author":"Jabes","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1179\/joc.2001.13.3.244","article-title":"In vitro evaluation of BI397, a novel glycopeptide antimicrobial agent","volume":"13","author":"Jones","year":"2001","journal-title":"J. Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijantimicag.2003.07.008","article-title":"Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide","volume":"23","author":"Jones","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib11","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1128\/AAC.48.3.1061-1064.2004","article-title":"Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin","volume":"48","author":"Lefort","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib12","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics and pharmacodynamics of intravenous dalbavancin in healthy volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib13","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/AAC.49.2.770-772.2005","article-title":"Antistaphylococcal activity of dalbavancin, an experimental glycopeptide","volume":"49","author":"Lin","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl S2","key":"10.1016\/j.diagmicrobio.2005.09.004_bib14","doi-asserted-by":"crossref","first-page":"ii21","DOI":"10.1093\/jac\/dki007","article-title":"In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide","volume":"55","author":"Lopez","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"issue":"Suppl S2","key":"10.1016\/j.diagmicrobio.2005.09.004_bib15","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/jac\/dki005","article-title":"Origin, structure and activity in vitro and in vivo of dalbavancin","volume":"55","author":"Malabarba","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib16","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMra011883","article-title":"Preventing complications of central venous catheterization","volume":"348","author":"McGee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib17","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1086\/320001","article-title":"Guidelines for the management of intravascular catheter-related infections","volume":"32","author":"Mermel","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib18","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A6","author":"National Committee for Clinical Laboratory Standards","year":"2003"},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib19","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1086\/344188","article-title":"Guidelines for the prevention of intravascular catheter-related infections","volume":"35","author":"O'Grady","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1072-7515(00)00266-0","article-title":"Bacteremia associated with central venous catheter infection is not an independent predictor of outcomes","volume":"190","author":"Pelletier","year":"2000","journal-title":"J. Am. Coll. Surg."},{"issue":"Suppl 2","key":"10.1016\/j.diagmicrobio.2005.09.004_bib21","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1086\/320187","article-title":"Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance program","volume":"32","author":"Pfaller","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin in the treatment of catheter-related bloodstream infections","volume":"40","author":"Raad","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0196-4399(03)80036-3","article-title":"Catheter-related infections\u2014diagnosis, treatment and prevention","volume":"25","author":"Schinabeck","year":"2003","journal-title":"Clin. Microbiol. Newsl."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib24","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","article-title":"Once-weekly dalbavancin versus standard of care antimicrobial regimens for treatment of skin and soft tissue infections","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib25","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1128\/JCM.38.7.2488-2493.2000","article-title":"Performance of phenotypic and genotypic methods to determine the clinical relevance of serial blood isolates of Staphylococcus epidermidis in patients with septicemia","volume":"38","author":"Sloos","year":"2000","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diagmicrobio.2003.09.004","article-title":"Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates","volume":"48","author":"Streit","year":"2004","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib27","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1128\/JCM.33.9.2233-2239.1995","article-title":"Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: Criteria for bacterial strain typing","volume":"33","author":"Tenover","year":"1995","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2005.09.004_bib28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1517\/13543784.12.2.117","article-title":"Novel agents for the treatment of resistant Gram-positive infections","volume":"12","author":"Woodford","year":"2003","journal-title":"Expert Opin. Investig. Drugs"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889305002270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889305002270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T13:06:37Z","timestamp":1586696797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889305002270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S0732889305002270"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2005.09.004","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}